Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia

Sponsor
Eli Lilly and Company (Industry)
Overall Status
Completed
CT.gov ID
NCT00034801
Collaborator
(none)
378
30
17.9
12.6
0.7

Study Details

Study Description

Brief Summary

This is a research study comparing the safety and efficacy of two active study medications

Condition or Disease Intervention/Treatment Phase
Phase 4

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
A Controlled Trial of Olanzapine Versus Active Comparator in the Treatment of Schizophrenic and Schizoaffective Subjects With Comorbid Depression
Study Start Date :
Sep 1, 2001
Study Completion Date :
Mar 1, 2003

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Male or female subjects 18-60 years of age

    • Female subjects of childbearing potential must be using a medically accepted means of contraception

    • Each subject must have a level of understanding sufficient to perform all tests and examinations required by the protocol

    • Subjects must be considered reliable

    Exclusion Criteria:
    • Treatment with a drug within the last 30 days that has not received regulatory approval at the time of study entry

    • Female subjects who are either pregnant or nursing

    • Uncorrected hypothyroidism or hyperthyroidism

    • Narrow-angle glaucoma

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Tuscaloosa Alabama United States
    2 Little Rock Arkansas United States
    3 Anaheim California United States
    4 Chula Vista California United States
    5 Lafayette California United States
    6 Long Beach California United States
    7 Orange California United States
    8 Poway California United States
    9 Rosemeade California United States
    10 San Diego California United States
    11 Denver Colorado United States
    12 New Britain Connecticut United States
    13 Winter Park Florida United States
    14 Augusta Georgia United States
    15 Prairie Village Kansas United States
    16 Gaithersburg Maryland United States
    17 Mt Pleasant Michigan United States
    18 St Louis Missouri United States
    19 Lincoln Nebraska United States
    20 Clementon New Jersey United States
    21 Buffalo New York United States
    22 New York New York United States
    23 Staten Island New York United States
    24 Charlotte North Carolina United States
    25 Philadelphia Pennsylvania United States
    26 Sioux Falls South Dakota United States
    27 Austin Texas United States
    28 El Paso Texas United States
    29 Houston Texas United States
    30 Salt Lake City Utah United States

    Sponsors and Collaborators

    • Eli Lilly and Company

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00034801
    Other Study ID Numbers:
    • 5529
    • F1D-US-HGJU
    First Posted:
    May 3, 2002
    Last Update Posted:
    Jul 19, 2006
    Last Verified:
    Jul 1, 2006

    Study Results

    No Results Posted as of Jul 19, 2006